Dermatology Immune Response Protein 
XTalks
OCTOBER 24, 2024
In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis. While research is still ongoing, studies suggest that low-calorie diets, the Mediterranean diet and protein restriction may reduce inflammation.
The Pharma Data
JUNE 19, 2022
This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine. Thus, the effect is better p53 pathway activation without the toxic effects seen with MDM inhibitors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 16, 2021
AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.
The Pharma Data
MARCH 16, 2021
These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 9 The PsA approval was based on results from DISCOVER-1 and DISCOVER-2, which showed TREMFYA reached each study’s primary endpoint of ACR 20 response at 24 weeks.
The Pharma Data
SEPTEMBER 15, 2020
20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.
The Pharma Data
AUGUST 11, 2020
In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
The Pharma Data
AUGUST 11, 2020
In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
Expert insights. Personalized for you.
105 
Let's personalize your content